Zhongsheng Pharma Stock Code: 002317 Performance Evaluation Report and Supervisory Responsibilities Report
In accordance with the "Agreement on Engagement of Auditing Services," the "Chinese Certified Public Accountants Auditing Standards," and other professional norms, as well as the company's 2025 annual report work arrangements, Huaxing LLP audited the company's 2025 financial report and the effectiveness of its internal control over financial reporting as of December 31, 2025. Additionally, it audited and issued special reports or explanations on the company's internal control, related party capital occupation by the controlling shareholder, and the collection, management, and use of raised funds.
Upon audit, Huaxing LLP opined that the company's financial statements were prepared in all material respects in accordance with the accounting standards for enterprises, fairly reflecting the company's consolidated and parent company financial position as of December 31, 2025, and its consolidated and parent company operating results and cash flows for 2025. The company maintained effective internal control over financial reporting in all aspects in accordance with the "Basic Norms for Enterprise Internal Control" and relevant regulations.
Huaxing LLP issued a standard unqualified audit report. During the audit process, Huaxing LLP communicated with the company's management regarding the independence of the accounting firm and relevant audit personnel, the composition of the audit team, the audit plan, risk assessment, fraud testing and evaluation methods, key audit areas for the year, audit adjustments, and preliminary audit opinions.